Provided by Tiger Trade Technology Pte. Ltd.

Disc Medicine

59.61
+0.50000.85%
Post-market: 59.610.00000.00%16:10 EDT
Volume:565.54K
Turnover:33.60M
Market Cap:2.27B
PE:-9.92
High:60.33
Open:59.00
Low:58.15
Close:59.11
52wk High:99.50
52wk Low:30.82
Shares:38.16M
Float Shares:32.89M
Volume Ratio:0.71
T/O Rate:1.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.0116
EPS(LYR):-6.0116
ROE:-35.86%
ROA:-22.55%
PB:3.07
PE(LYR):-9.92

Loading ...

FDA Grants Priority Review to Disc Medicine’s Bitopertin NDA

Reuters
·
Jan 12

Disc Medicine Granted Composition of Matter Patent for DISC-0974, Ensuring Exclusivity Until 2041

Reuters
·
Jan 12

Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026

GlobeNewswire
·
Jan 12

A Look At Disc Medicine (IRON) Valuation After Bitopertin NDA Filing And Positive DISC-0974 Phase 2 Data

Simply Wall St.
·
Jan 09

Disc Medicine’s Cash Runway And NDA Milestones Could Be A Game Changer For IRON

Simply Wall St.
·
Jan 06

Disc Medicine Chief Legal Officer Rahul Khara Reports Disposal of Common Shares

Reuters
·
Jan 06

Seadrill, Vestis, Mastercraft Boat, and More Stocks See Action From Activist Investors -- Barrons.com

Dow Jones
·
Dec 27, 2025

Press Release: CHAMPION IRON TO LAUNCH CASH TENDER OFFER TO ACQUIRE RANA GRUBER, RECEIVES FINANCIAL SUPPORT FROM LA CAISSE AND A TERM LOAN COMMITMENT FROM SCOTIABANK

Dow Jones
·
Dec 22, 2025

Disc Medicine (IRON) Valuation Check as FDA Scrutiny and Bitopertin Trial Milestones Drive Volatility

Simply Wall St.
·
Dec 21, 2025

BUZZ-Disc Medicine drops on report of FDA skepticism over rare blood disorder drug

Reuters
·
Dec 20, 2025

Director Kevin Bitterman Reports Disposal of Disc Medicine Inc. i Common Shares

Reuters
·
Dec 19, 2025

Disc Medicine Chief Medical Officer William Jacob Savage Sells Common Shares

Reuters
·
Dec 17, 2025

Disc Medicine Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Dec 16, 2025

Disc Medicine CEO John D. Quisel Reports Sale of Common Shares

Reuters
·
Dec 16, 2025

Press Release: LABRADOR IRON ORE ROYALTY CORPORATION - CASH DIVIDEND FOR THE FOURTH QUARTER OF 2025 - $0.35 PER COMMON SHARE

Dow Jones
·
Dec 11, 2025

Disc Medicine (IRON): Reassessing Valuation After Encouraging RALLY-MF Phase 2 Anemia Data

Simply Wall St.
·
Dec 10, 2025

Disc Medicine Reports Positive Phase 2 Trial Results for DISC-0974 in Myelofibrosis-Related Anemia

Reuters
·
Dec 06, 2025

Disc Medicine Presents Positive Initial Data From Rally-Mf Phase 2 Trial in Patients With Myelofibrosis (Mf) and Anemia at the 67TH American Society of Hematology (Ash) Annual Meeting

THOMSON REUTERS
·
Dec 06, 2025

Disc Medicine Inc : Jefferies Raises Target Price to $154 From $127

THOMSON REUTERS
·
Nov 29, 2025

Disc Medicine’s Growth Potential Driven by Innovative Treatments and Promising Market Opportunities

TIPRANKS
·
Nov 19, 2025